Pfizer, Lilly, Sanofi, Amgen And Others Named In Indian Clinical Trial Death Compensation Inquiry
This article was originally published in The Pink Sheet Daily
Executive Summary
The news of the health ministry probe earlier this month stirred debate about the gaping holes in Indian clinical trial laws and the country's loose enforcement framework, particularly as clinical trial projects flow rapidly into the country.
You may also be interested in...
India Launches Probe Following Damning Evidence Of Irregularities In Product Approvals
Government assembles committee to investigate validity of drug approvals without required clinical trials in India.
India Launches Probe Following Damning Evidence Of Irregularities In Product Approvals
Government assembles committee to investigate validity of drug approvals without required clinical trials in India.
Patient Safety First: Indian Regulator Takes Steps To Tighten Grip Over Site Inspections, Ensure Data Credibility
MUMBAI - As India moves rapidly to become an integral part of large-scale global clinical trials, the Central Drugs Standard Control Organization under the Ministry of Health and Family Welfare has declared a set of new guidelines to ensure adequate safety of trial participants